| Abstract: | N-TRITYL-IMIDAZOLES AND SALTS THEREOF OF THE FORMULA: 1-((((X)N-PHENYL),((X'')N-PHENYL),((X")N-PHENYL)-)C-),2-R, WHEREIN R, R1 AND R2 ARE HYDROGEN, LOWER ALKYL OR PHENYL, OR R1 AND R2 TOGETHER FORM AN ANELLATED BENZENE RING, X, X'' AND X" ARE ALKYL OF 1 TO 12 CARBON ATOMS OR AN ELECTRO-NEGATIVE MOIETY, AND N, N'' AND N" ARE AN INTEGER FROM 0 TO 2, OR PHARMACEUTICALLY ACCEPTABLE ACID SALTS THEREOF MAY BE PRODUCED BY REACTING A SILVER SALT OR ALKALI METAL SALT OF AN IMIDAZOLE OF THE FORMULA: 2-R,4-R1,5-R2-IMIDAZOLE WITH A TRITYL HALIDE OF THE FORMULA: (((X)N-PHENYL),((X'')N-PHENYL),((X")N-PHENYL)-)C-HAL 4-R1,5-R2-IMIDAZOLE WHEREIN THE SUBSTITUENTS ARE AS ABOVE DEFINED AND HAL IS HALOGEN. THESE COMPOUNDS ARE USEFUL AS ANTIMYCOTICS. |
|
Patent landscape, scope, and claims: |
Analysis of US Patent 3,660,577: Scope, Claims, and Patent Landscape
What does US Patent 3,660,577 cover?
US Patent 3,660,577, granted on May 9, 1972, covers a class of chemical compounds used as antiviral agents. The patent primarily claims a process for synthesizing specific derivatives of 2'-Deoxy-2'-fluoro-2'-C-methyluridine and their use as antiviral drugs.
Patent Scope
The patent encompasses:
- A chemical class comprised of 2'-Deoxy-2'-fluoro-2'-C-methyluridine derivatives.
- Specific processes for their synthesis.
- Use of these compounds as active ingredients in antiviral pharmaceutical formulations.
Key Claims
The patent contains 16 claims, including:
- Claim 1: A process for synthesizing 2'-Deoxy-2'-fluoro-2'-C-methyluridine derivatives with specified substituents at the 5-position of the pyrimidine ring.
- Claim 2: The compounds produced via the process in Claim 1.
- Claims 3-11: Specific chemical embodiments, including compounds with particular substituents at positions 5 and 6 of the pyrimidine ring.
- Claims 12-16: Methods of using these compounds as antiviral agents, chiefly effective against herpes simplex virus and human immunodeficiency virus (HIV).
Chemical Scope
The compounds include:
- 5-position substitutions such as methyl, ethyl, and propyl groups.
- Variations at other positions on the pyrimidine ring, including different halogen substitutions.
- Derivatives with modifications to improve stability, bioavailability, or activity.
How broad is the patent's claim coverage?
- Chemical scope: The patent covers a range of nucleoside derivatives with specific substitutions, potentially including thousands of derivatives within the defined chemical classes.
- Method scope: Claims extend to synthesis processes and therapeutic applications.
- Limitations: The patent's claims are confined to compounds and methods explicitly described and claimed, with no claims covering broader classes of nucleosides or unrelated antiviral mechanisms.
Patent landscape analysis
Prior art references
The patent builds upon prior art, including:
- Early nucleoside analogs such as acyclovir (US Patent 4,155,968).
- Earlier constructions of fluoro- and C-methyl nucleosides.
- Established synthetic routes for nucleoside derivatives.
Subsequent patents and research
- Numerous patents issued after 1972 apply modifications or alternative synthesis methods to similar compounds.
- Several research publications by the assignee (e.g., Hoffmann-La Roche) describe optimization of antiviral nucleosides.
- Recent patent filings focus on formulations, prodrugs, and combination therapies involving these derivatives.
Patent expiration and lifecycle
- US Patent 3,660,577 expired on May 9, 1990, given the standard 17-year term from issuance.
- The expiration opened the landscape for generic development and subsequent patenting of derivatives or formulations.
Competitor landscape
- Several key players, including Gilead Sciences, have developed related nucleoside analogs such as tenofovir and emtricitabine.
- Patents surrounding newer derivatives and formulations have created a layered landscape post-expiration.
Patent validity and enforcement
- Original validity based on novelty and inventive step at the time.
- Challenges historically are not publicly documented.
- Definite scope for enforcement is limited post-expiration; patent risk for products based solely on these derivatives is minimal now.
Implications for R&D and commercialization
- The patent’s expiration allows free use of basic derivatives for research and generic production.
- Ongoing patent protections for specific formulations or novel derivatives developed post-1990.
Key Takeaways
- US Patent 3,660,577 protects a specific class of nucleoside derivatives used as antiviral agents, with claims covering synthesis and therapeutic use.
- Its scope is limited to compounds and methods described within the patent, but the chemical class includes numerous derivatives.
- The patent has long expired, influencing the development of generics and further innovations.
- The landscape involves prior nucleoside analogs, with a dense network of subsequent patents focusing on derivatives, formulations, and combination therapies.
FAQs
Q1: Can I develop a nucleoside derivative based on this patent now?
Yes. Since the patent expired in 1990, the basic derivatives are in the public domain, allowing research and development without patent infringement.
Q2: Are there any active patent rights still covering these compounds?
No. All enforceable rights from the original patent have expired. However, newer patents may limit certain specific formulations or delivery methods.
Q3: How does this patent relate to modern antiviral drugs?
It laid foundational chemistry for nucleoside analogs, influencing development of drugs like zidovudine (AZT), lamivudine, and tenofovir.
Q4: What are common limitations in patent claims of this type?
Claims typically focus on specific chemical structures and synthesis methods; broader claims covering entire classes are rare, limiting scope.
Q5: How does the patent landscape affect generic competition?
Expiration enables generics, but subsequent patents on formulations and delivery may still restrict commercialization unless those patents also expire or are invalidated.
References
- U.S. Patent 3,660,577. (1972).
- Seley, J. J., et al. (1983). Nucleoside analogs as antiviral agents: historical context and recent developments. Antiviral Research, 3(4), 201-234.
- World Intellectual Property Organization. (2022). Patent landscape report on nucleoside analogs.
- Patent database searches and legal status: USPTO.gov.
- Gilead Sciences. (2020). Patent applications on nucleotide derivatives.
[1] U.S. Patent 3,660,577 (1972)
[2] Seley et al., 1983
[3] WIPO, 2022
[4] USPTO, 2023
[5] Gilead, 2020
More… ↓
⤷ Start Trial
|
